학술논문
Effects of Short-Term Potassium Chloride Supplementation in Patients with CKD
Document Type
Article
Author
Gritter, Martin; Wouda, Rosa D.; Yeung, Stanley M.H.; Wie?rs, Michiel L.A.; Geurts, Frank; de Ridder, Maria A.J.; Ramakers, Christian R.B.; Vogt, Liffert; de Borst, Martin H.; Rotmans, Joris I.; Hoorn, Ewout J.; Boom, Henk; de Graaf Gasthuis, Reinier; Gabre?ls, Bas Ah.T.F.; Groeneveld, Marc; Janssen, Wilbert M.T.; Korte, Mario R.; Laverman, Goos D.; van der Lubbe, Nils; van der Net, Jeroen B.; Soonawala, Darius; Swart, Reinout M.; Verhoeven, Martine A.M.
Source
Journal of the American Society of Nephrology; September 2022, Vol. 33 Issue: 9 p1779-1789, 11p
Subject
Language
ISSN
10466673; 15333450
Abstract
Observational studies show health benefits from a higher potassium intake, but it is unknown if this is tolerated by patients with CKD. This 2-week study indicates that 40 mmol/day potassium chloride supplementation (the estimated gap between actual and adequate intake) increased plasma potassium by 0.4 mmol/L in 191 patients with CKD (eGFR 31 ml/min per 1.73 m2, 83% on renin-angiotensin inhibitors). The majority of patients (89%) remained normokalemic. Higher baseline plasma potassium and older age were risk factors for developing hyperkalemia after supplementation. Potassium chloride supplementation did not lower office BP, but did cause a tendency toward hyperchloremic metabolic acidosis. Longer-term studies should determine whether the cardiorenal benefits of adequate dietary potassium intake outweigh the risk of hyperkalemia in patients with CKD.